{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,4,27]],"date-time":"2025-04-27T14:10:04Z","timestamp":1745763004266,"version":"3.40.4"},"reference-count":24,"publisher":"BMJ","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Case Reports"],"accepted":{"date-parts":[[2018,10,9]]},"abstract":"<jats:p>We report a case of a hospitalised patient who developed probable serotonin toxicity shortly after the initiation of linezolid in whom the selective serotonin reuptake inhibitor (SSRI) escitalopram had been recently discontinued. On day 2 of linezolid administration, the patient reported severe anxiety and was observed to have full body jerking and twitching motions without mental status change. Notably, the patient was concomitantly receiving the antidepressant, trazodone and the benzodiazepine, clonazepam possibly affecting the severity and manifestations of serotonin toxicity. Linezolid was discontinued after 5 days and the patient\u2019s symptoms resolved. Serotonin toxicity can present with an array of symptoms and be life threatening if left unrecognised. This report highlights the clinical lessons that discontinuation of an SSRI upon initiation of linezolid does not eliminate the risk of serotonin toxicity and that other concomitant medications may worsen or improve some of the symptoms lending delay and uncertainty to the diagnosis.<\/jats:p>","DOI":"10.1136\/bcr-2018-226597","type":"journal-article","created":{"date-parts":[[2018,10,31]],"date-time":"2018-10-31T05:55:12Z","timestamp":1540965312000},"page":"bcr-2018-226597","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":3,"title":["Linezolid-associated serotonin toxicity after escitalopram discontinuation: concomitant drug considerations"],"prefix":"10.1136","volume":"2018","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6764-5263","authenticated-orcid":false,"given":"Adonice","family":"Khoury","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6021-0347","authenticated-orcid":false,"given":"Martin","family":"Runnstrom","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alex","family":"Ebied","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ellen S","family":"Penny","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2018,10,30]]},"reference":[{"key":"2025042706395430000_2018.oct30_1.bcr-2018-226597.1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2003.11.003"},{"key":"2025042706395430000_2018.oct30_1.bcr-2018-226597.2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra041867"},{"key":"2025042706395430000_2018.oct30_1.bcr-2018-226597.3","unstructured":"Center for Drug Evaluation and Research. Drug Safety and Availability - FDA Drug Safety Communication: Updated information about the drug interaction between linezolid (Zyvox) and serotonergic psychiatric medications: U S Food and Drug Administration Home Page, Center for Drug Evaluation and Research, 2017. https:\/\/www.fda.gov\/Drugs\/DrugSafety\/ucm265305.htm. (Accessed 3rd Mar 2018)."},{"key":"2025042706395430000_2018.oct30_1.bcr-2018-226597.4","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkr467"},{"key":"2025042706395430000_2018.oct30_1.bcr-2018-226597.5","doi-asserted-by":"publisher","DOI":"10.1086\/524671"},{"key":"2025042706395430000_2018.oct30_1.bcr-2018-226597.6","doi-asserted-by":"publisher","DOI":"10.1176\/appi.psy.46.3.274"},{"key":"2025042706395430000_2018.oct30_1.bcr-2018-226597.7","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkh257"},{"key":"2025042706395430000_2018.oct30_1.bcr-2018-226597.8","doi-asserted-by":"publisher","DOI":"10.1086\/503839"},{"key":"2025042706395430000_2018.oct30_1.bcr-2018-226597.9","doi-asserted-by":"crossref","first-page":"413","DOI":"10.4103\/0253-7176.122245","article-title":"Linezolid-induced near-fatal serotonin syndrome during escitalopram therapy: case report and review of literature","volume":"35","author":"Kulkarni","year":"2013","journal-title":"Indian J Psychol Med"},{"key":"2025042706395430000_2018.oct30_1.bcr-2018-226597.10","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1515\/DMDI.2010.001","article-title":"Linezolid interaction with serotonin reuptake inhibitors: report of two cases and incidence assessment","volume":"25","author":"Go","year":"2010","journal-title":"Drug Metabol Drug Interact"},{"key":"2025042706395430000_2018.oct30_1.bcr-2018-226597.11","doi-asserted-by":"publisher","DOI":"10.2190\/PM.38.1.h"},{"key":"2025042706395430000_2018.oct30_1.bcr-2018-226597.12","doi-asserted-by":"publisher","DOI":"10.1592\/phco.26.2.269"},{"key":"2025042706395430000_2018.oct30_1.bcr-2018-226597.13","doi-asserted-by":"publisher","DOI":"10.1345\/aph.1R604"},{"key":"2025042706395430000_2018.oct30_1.bcr-2018-226597.14","doi-asserted-by":"publisher","DOI":"10.1086\/340710"},{"key":"2025042706395430000_2018.oct30_1.bcr-2018-226597.15","doi-asserted-by":"publisher","DOI":"10.1086\/504809"},{"key":"2025042706395430000_2018.oct30_1.bcr-2018-226597.16","doi-asserted-by":"publisher","DOI":"10.1093\/qjmed\/hcg109"},{"key":"2025042706395430000_2018.oct30_1.bcr-2018-226597.17","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/27.4.405"},{"key":"2025042706395430000_2018.oct30_1.bcr-2018-226597.18","doi-asserted-by":"crossref","unstructured":"Man BL , YP F . Piperacillin\/tazobactam-induced myoclonic jerks in a man with chronic renal failure. BMJ Case Rep 2015:pii: bcr2015210184 [Epub ahead of print 7 MAy 2015].","DOI":"10.1136\/bcr-2015-210184"},{"key":"2025042706395430000_2018.oct30_1.bcr-2018-226597.19","doi-asserted-by":"publisher","DOI":"10.1345\/aph.1H423"},{"key":"2025042706395430000_2018.oct30_1.bcr-2018-226597.20","unstructured":"Zyvox. (linezolid) package insert. New York, NY: Pharmacia & Upjohn Company, 2018."},{"key":"2025042706395430000_2018.oct30_1.bcr-2018-226597.21","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkr072"},{"key":"2025042706395430000_2018.oct30_1.bcr-2018-226597.22","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00258-17"},{"key":"2025042706395430000_2018.oct30_1.bcr-2018-226597.23","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1017\/S1092852900024020","article-title":"Mechanism of action of trazodone: a multifunctional drug","volume":"14","author":"Stahl","year":"2009","journal-title":"CNS Spectr"},{"key":"2025042706395430000_2018.oct30_1.bcr-2018-226597.24","unstructured":"Stahl SM . Chapter 7: Antidepressants. In: Stahl\u2019s essential psychopharmacology: neuroscientific basis and practical applications. 4th edn: Cambridge University Press, 2013:326."}],"container-title":["BMJ Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bcr-2018-226597","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,27]],"date-time":"2025-04-27T13:40:05Z","timestamp":1745761205000},"score":1,"resource":{"primary":{"URL":"https:\/\/casereports.bmj.com\/lookup\/doi\/10.1136\/bcr-2018-226597"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10,30]]},"references-count":24,"alternative-id":["10.1136\/bcr-2018-226597"],"URL":"https:\/\/doi.org\/10.1136\/bcr-2018-226597","relation":{},"ISSN":["1757-790X"],"issn-type":[{"type":"electronic","value":"1757-790X"}],"subject":[],"published":{"date-parts":[[2018,10,30]]}}}